RhoVac announces the completion of patient recruitment for the BRaVac clinical phase IIb study of RV001 in prostate cancer
RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on Sep 20[th] , 2021, that its clinical phase IIb study of lead drug candidate RV001 in prostate cancer, BRaVac, is deemed fully recruited and that no additional patients will be screened after this week. Top-line results of the study are estimated to be at hand in the first half of 2022.RhoVac started the clinical phase IIb trial (BRaVac) of RV001 in late 2019, targeting prostate cancer patients with a biochemical recurrence (a rise in PSA) after curative intent therapy. In November of 2020, RhoVac was awarded